Dr. Boro Dropulić, Executive Director of Caring Cross, discusses with Ankit Kankar of BioSpectrum Asia how their mission to reduce CAR-T therapy costs is transforming global healthcare, with a focus on access in low- and middle-income countries.
In a candid conversation with Ankit Kankar from BioSpectrum Asia, Dr. Boro Dropulić, Executive Director of Caring Cross, delves into the motivations behind Caring Cross’s groundbreaking efforts to make CAR-T cell therapies more affordable. Drawing from decades of experience in the cellular gene therapy field, Dr. Dropulić shares how Caring Cross’s decentralized manufacturing model is driving down costs and enabling access to life-saving treatments, particularly in low- and middle-income countries. He also highlights key partnerships, including with Brazil’s Fiocruz, that are central to their mission of improving global healthcare equity.
